New enterprises have exceeded 10,000, and the construction of the "two districts" in Changping District is fruitful!

Author:Beijing Changping officially r Time:2022.07.28

Continue to do the three major leading industries of pharmaceutical health, advanced energy, and intelligent manufacturing. Changping District has introduced the city's first industrial support policy for free trade zone "Interim Measures for the Development of Medical and Health Industry", with special funds for 250 million yuan ... Changping District has made a result of promoting the construction of the "two districts". From January to May this year, there were 10,665 new companies in our district, an increase of 9.62%year -on -year. There were 33 new foreign -funded enterprises. The actual use of foreign capital was 357 million US dollars, an increase of 183.96%year -on -year.

At Beijing Hutang Shenghua Medical Technology Co., Ltd. in Zhongguancun Life Sciences, scientific researchers are debugging equipment on cell and gene therapy innovation platforms. Relying on the technical advantages of the Tsinghua Institute of Industry and Research Institute of Cell and Gene Treatment Innovation, a platform that meets the standards of cells and gene therapy and China -testing and Chinese -testing and Chinese testing and the European trials of China, the United States, and the European Union is built. Trial and industrial production support for the industrial chain.

"The scale is not critical. Multiple batches of orders, fast production capacity, low cost, and short cycle are core competitiveness. Our CDMO production platform is the core engine to promote the development of the biopharmaceutical industry." Hao Guoshun told reporters that the full name of CDMO in Chinese is a contract R & D and production organization. It is a kind of outsourcing service for drug research and development and production. , Register and verify the production and commercialization of customized R & D and production services.

CDMO has two characteristics, one is "custom development", and the other is "customized production", allowing small and medium -sized drug manufacturers to replace simple production capacity output with high value -added technology. At different stages of R & D and production, CDMO companies can use their own professional and large -scale advantages to directly serve pipeline companies to help customers save costs, improve success rates and efficiency.

It is understood that the cell and gene therapy innovation centers include 7,000 square meters of cells and gene therapy R & D and Chinese test platforms, as well as 3,000 square meters of hard technology incubators. At present, more than 10 cells and genetic therapy technology enterprises can provide innovative drug research and development and clinical experimental services.

"During this period, the Changping District Government and various committees and bureaus gave us funding, policies, coordinating the positive circulation of various resources to form the industrial chain." Hao Guoshun told reporters that the company will strive for better CDMO production next step Services, conforming to the good trend of the construction of the two districts of Changping, provide better services for pipeline companies in Changping District and even the country.

Since the beginning of this year, the district has accumulated 176 projects in the warehouse in 2022 (including 11 foreign projects), of which 78 projects have been implemented; 74 surplus projects in 2021 have been steadily promoted. Relying on the four major professional service platforms, including the newborn nest, dart darts, Heitangshenghua, and the International Precision Medicine Acceleration Center, have introduced 51 innovative projects and 41 new registered or moved into the main company; the focus is on 5 projects such as Kunlun Beidou Essence

In the future of the Zhongguancun Life Sciences Park in Science City, the dart accelerator that has been currently in this year has settled in multiple "innovative seeds" of medicine and health. Due to the long R & D cycle and high investment in R & D, medical health is considered one of the areas with the highest threshold for innovation and entrepreneurship.

"Some companies currently settled in our dart international innovation platform are some of the start -up small and micro enterprises, and some belong to enterprises that have rising rapidly. These types of companies need to expand the R & D team and increase experimental space. It is difficult for them to find them in the short term. Carry out the place where R & D experiments are carried out immediately, and we can fully meet their needs here. "Zhu Pengcheng, founder of ATLATL dart accelerator, told reporters that the innovation platform has the standard for the international biomedical research and development laboratory standard, designing and building a Class A -level sharing experiment Room, independent laboratory, pre -clinical research laboratory and other platforms, integrated R & D, office, conferences, business services and other functions.

All companies that settled in the dart platform can not only obtain all resources and supporting support required for the project research and development, but also reduce risks and costs, and truly realize the "bags" of innovative projects.

According to reports, there are currently many seeds on the ATLATL open platform. The emerging leader of innovation research and clinical development of the tumor field, Fan Enshi Company, has been determined by the PT217, which is used to treat small cell lung cancer to obtain orphan drugs (FDA). In the field of new drug development, especially macromolecular drugs, Hua Shenzhi Pharmaceuticals innovatively developed high -efficiency machine learning algorithms and data acquisition technology, and reconstructed drug development processes, which greatly improved the speed and efficiency of new drug research and development.

It is understood that the first phase of the Beijing Darts International Innovation Platform has been put into use. The second phase of the innovation platform is expected to be completed and put into use at the end of the year. At that time, nearly 50 companies can be served.

Good projects are attracted by a group of first -character policies. In recent years, Changping has successively introduced a number of methods and policies to support the development of enterprises and accelerate the cultivation of enterprises, including tax discounts, talent introduction, funding support and rewards, and corporate qualifications.

In terms of biomedicine, Changping District helped Nocheng Jianhua take the lead in enjoying the policy of "allowing drug listing permits as the main body of the drug sun procurement platform"; ; Implement the "Open Implementation Plan for the Open Industry Chain of Beijing Biomedicine", establish a dual dispatch mechanism for the construction of the district pharmaceutical and health, and the construction of the "two districts" construction, and do a good job of policies and guarantee. In terms of advanced energy, the "Changping District Advanced Energy Industry Property Improvement Action Plan (2022-2025)" is released to strengthen the supply of factors and allows policy dividends to fully benefit the enterprise.

In terms of talent introduction, the "Implementation Measures for the Implementation of Talent Housing Subsidies in Changping District", "Changping District Approval of the" Administrative Measures for the "Beijing Work Residence Permit" and the third batch of "Changju Project" high -level science and technology talent development fund support plan will be issued, and the issuance of high -level science and technology talents will be issued. The "Changju Project" rewarded funds of 34.33 million yuan, supporting talent (team) and development platform projects.

In the next step, our district will focus on historical opportunities, focusing on the goal of "building the two districts' to build Changping models", accelerate the opening of the open development of the entire industry chain of the leading industry, actively plan a new round of policy innovation, and strive to bring Changping "two districts in the two districts. "The policy advantage of construction and the transformation of industrial advantages into higher quality and higher levels of development advantages.